Tempus and Stemline Therapeutics Announce Collaboration to Implement Tempus Next to Support Patients with Metastatic Breast Cancer
“We are thrilled to enter this collaboration with Tempus, a leader in leveraging AI to advance precision medicine and patient care. ESR1 mutations can stop tumors from responding to standard endocrine therapy, in turn causing the cancer to progress. With an approved treatment that targets these mutations, the identification of ESR1 is a critical step in customizing care for patients with ER+, HER2- metastatic breast cancer,” said Yasir Nagarwala, Senior Vice President, Medical Affairs, Stemline Therapeutics, Inc. “At Menarini Stemline, we are focused on bringing transformational therapies to patients living with cancer, and by partnering with companies like Tempus, we are able to help physicians understand when testing for an ESR1 mutation may be appropriate.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome